-+ 0.00%
-+ 0.00%
-+ 0.00%

NewcelX FY25 net loss widens to USD 8.3 million; operating loss rises to USD 2.56 million

PUBT·04/29/2026 21:03:45
Listen to the news
NewcelX FY25 net loss widens to USD 8.3 million; operating loss rises to USD 2.56 million
  • NewcelX posted a total loss of USD 8.3 million for fiscal 2025, widening from 2024.
  • Revenue remained at no revenue.
  • Operating loss expanded to USD 2.56 million, driven by first-time consolidation of NLS operations, higher public-company compliance costs, higher stock-based compensation.
  • Cash and cash equivalents totaled USD 2.2 million at Dec. 31, 2025, with accumulated deficit at USD 84.9 million.
  • Management said existing cash is not sufficient to fund one year of operating requirements, while it explores financing options and points to a USD 25 million committed equity facility plus a USD 1.35 million April 2026 private placement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-049307), on April 29, 2026, and is solely responsible for the information contained therein.